The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | Sequencing of BTK inhibitors in CLL
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the sequencing of BTK inhibitors in chronic lymphocytic leukemia (CLL). The currently approved BTK inhibitors are all covalent inhibitors, meaning sequencing is not advisable if a patient progresses. Dr Brown highlights the potential of non-covalent BTK inhibitors, such as pirtobrutinib, for treatment following patient progression on covalent BTK inhibitors. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
